MinorDirect oral anticoagulants (factor Xa inhibitors)×Selective mineralocorticoid receptor antagonist
Updated · Methodology
Mechanism
CYP3A4/5 is the main enzyme that metabolises apixaban in the liver, and apixaban is also a substrate of the transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). For these pathways, the apixaban summary of product characteristics (SmPC) restricts only strong inhibitors and inducers of both CYP3A4 and P-gp (apixaban SmPC, European Medicines Agency, EMA, sections 4.5 and 5.2). CYP3A4 also metabolises eplerenone, but in vitro eplerenone did not inhibit this enzyme. It is neither a substrate nor an inhibitor of P-gp (eplerenone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). In vitro, apixaban did not inhibit CYP3A4 either, so it is not expected to change the elimination of drugs metabolised by this enzyme (apixaban SmPC, EMA, section 4.5). The documents do not address this combination. Among anticoagulants, the eplerenone documents name only warfarin, and no clinically significant pharmacokinetic interaction with it was found (eplerenone SmPC, AEMPS, section 4.5; eplerenone label, US Food and Drug Administration, FDA, section 12.3).
Symptoms
The documents describe no symptoms linked to this combination. The main risk of apixaban is bleeding: bleeding, bruising, nosebleeds and haematomas are common (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.8). Severe bleeding can be fatal (apixaban label, US Food and Drug Administration, FDA, section 5.2). Eplerenone can raise blood potassium. Dizziness, fainting, headache, low blood pressure, nausea, diarrhoea and cough are also common (eplerenone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.4 and 4.8).
Management
According to the documents, the combination is acceptable, and the doses of apixaban and eplerenone need no change. Eplerenone is not among the drugs that the apixaban SmPC lists for cautious use or advises against combining with apixaban (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA, sections 4.4 and 4.5). Apixaban is not among the drugs restricted in the eplerenone SmPC either. These are strong and moderate CYP3A4 inhibitors and inducers, potassium-sparing diuretics, potassium supplements and other drugs that affect potassium or blood pressure (eplerenone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). Serum potassium is measured at the start of eplerenone treatment and at every dose change, and then regularly, especially in older people and in people with impaired renal function or diabetes (eplerenone SmPC, AEMPS, section 4.4). Eplerenone is contraindicated when the glomerular filtration rate is below 30 mL/min/1.73 m² (eplerenone SmPC, AEMPS, section 4.3). In non-valvular atrial fibrillation with creatinine clearance of 15–29 mL/min, apixaban is given at 2.5 mg twice daily, and below 15 mL/min it is not recommended (apixaban SmPC, EMA, section 4.4). People taking apixaban are monitored closely for signs of bleeding, and apixaban is stopped if severe bleeding occurs (apixaban SmPC, EMA, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Inspra (eplerenone) prescribing information (2018)– FDA Inspra label, Warnings §5.1 and Drug Interactions §7; DailyMed setid 1a52bedc-8e2c-4116-a296-a87770676b4a
- AEMPS: Ficha técnica de Eliquis 5 mg comprimidos recubiertos con película (apixabán) (2026)– AEMPS, CIMA (texto EMA), nº registro 111691009, secciones 4.4 y 4.5
- FDA: Eliquis (apixaban) prescribing information (2025)– FDA, DailyMed, Eliquis, E.R. Squibb & Sons, setid e9481622-7cc6-418a-acb6-c5450daae9b0, revisión 04/2025, secciones 4 y 7.1
- AEMPS: Ficha técnica: Eplerenona, Inspra 25 mg (nº registro 66356), secciones 4.3, 4.4 y 4.5 (2025)– AEMPS, CIMA, nº registro 66356, documento 01/2025 (fecha de revisión del texto 01/2024), secciones 4.3, 4.4 y 4.5